Azithromycin Pd.Sol.Inf 500mg/Vial (EU CTD Available)

  • Azithromycin Pd.Sol.Inf 500mg/Vial (EU CTD Available) 1
  • Azithromycin Pd.Sol.Inf 500mg/Vial (EU CTD Available) 2
Product Description

Azithromycin 500mg/Vial Powder for Solution for Infusion Reference Product: Zithromax® / PFIZER 
Description: Azithromycin as powder for solution for infusion is indicated for the treatment of community-acquired pneumonia due to susceptible microorganisms in adult patients where initial intravenous therapy is required and for the treatment of pelvic inflammatory disease (PID) due to susceptible microorganisms, in patients where initial intravenous therapy is required. 
Dossier Status EU CTD Available 
Stability Studies Zone II / Zone IVb 
Shelf life: Three (3) years 
Batch Size 22,640 vials 
Pack Size BT x 1 vial

Read more Show less

ANFARM HELLAS S.A.

  • GR
  • 2015
    On CPHI since
View company profile
Categories
more categories Show less
Specifications
  • Selling Points
    International Approvals/Standards
  • Supplied from
    Greece
More specifications Fewer specifications
Sales Markets
Show more Show less

ANFARM HELLAS S.A.

  • GR
  • 2015
    On CPHI since
View company profile

More Products from ANFARM HELLAS S.A. (4)

  • Amikacin Inj.Sol 500mg/2ml (EU CTD Available) & 1g/4ml (EU CTD Available: Q3 2021)

    Product Amikacin Inj.Sol 500mg/2ml (EU CTD Available) & 1g/4ml (EU CTD Available: Q3 2021)

    Amikacin Solution for Injection 
    Reference Product: Briklin® / BRISTOL-MYERS SQUIBB
    Description: Amikacin sulfate is indicated in the short-term treatment of serious infections due to susceptible strains of Gram-negative bacteria, including Pseudomonas species,&nb...
  • Apixaban F.C. Tabs 2.5mg/tab & 5mg/tab (under development)

    Product Apixaban F.C. Tabs 2.5mg/tab & 5mg/tab (under development)

    Apixaban Film Coated Tablets 2.5mg & 5mg
    Reference Product: Eliquis® / Bristol-Myers Squibb/Pfizer
    Description: Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transie...
  • Brivaracetam Oral Solution 10mg/ml (EU CTD Available: Q4 2022)

    Product Brivaracetam Oral Solution 10mg/ml (EU CTD Available: Q4 2022)

    Brivaracetam 10mg/ml Oral Solution
    Reference Product: Briviact® / UCB
    Description: Brivaracetam is an antiepileptic agent which is indicated as adjunctive therapy in the treatment of partial onsetseizures with or without secondary generalization in adults, adolescents and children from 4 year...
  • Brivaracetam Sol. Inf 10mg/ml (5ml Vial) (EU CTD Available: Q3 2022)

    Product Brivaracetam Sol. Inf 10mg/ml (5ml Vial) (EU CTD Available: Q3 2022)

    Brivaracetam 10mg/ml (5ml Vial) Solution for Injection/Infusion
    Reference Product: Briviact® / UCB
    Description: Brivaracetam is an antiepileptic agent which is indicated as adjunctive therapy in the treatment of partial onsetseizures with or without secondary generalization in adults, adolescents and...

ANFARM HELLAS S.A. resources (2)